RE: The house is so quiet19 Nov 2020 16:04
Nolupus, TM talked about biomarkers in the European Population which showed significant immune responses in comparison to other trialists. He also stated that Lupuzor failed because of the P3 trial design. What in your opinion do you think Avion will want to change in this trial? Go for a lower number on the SLEDAI score or recruit from a particular area?
Or a combination of both.
FWIW, I think the SPA is a given and Avion will naturally try and submit a trial that has already proved to be a success based on the last one. In other words make this trial fit the results. Efficacy is the only issue with Lupuzor, not safety.